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Having cholesterol in our body is essential for living 
healthy, but too much can lead to serious health problems, 
including—but not limited to—heart attacks and strokes (1). 
Indeed, accumulating evidence points to cholesterol as a 
cancer risk factor especially in colon, rectal, prostatic and 
testicular cancer (2). Cholesterol is the most abundant sterol 
in animal tissues with many important functions that spans 
from simply maintaining cell membrane physical properties 
to the production of bile acids and biosynthesis of steroid 
hormones. For the most part, cholesterol is synthetised 
de novo in the liver, but some is obtained from dietary intake. 
The synthesis of cholesterol takes place in the cytoplasm 
and the endoplasmic reticulum (ER) of hepatocytes (the 
major liver cell types) and starts with one molecule of 
acetyl-CoA. Through a series of enzymatic reactions, 
acetyl-CoA is converted into farnesyl pyrophosphate, which 
undergoes condensation to form squalene and then the 
direct precursors of cholesterol, lathosterol and desmosterol 
(1,2). The liver is also the main site of cholesterol 
catabolism resulting in the formation of bile acids and 
oxysterols (oxidized cholesterol derivatives) such as 
27-hydroxycholesterol and 25-hydroxycholesterol generated 
through the enzymatic activity of the cytochrome P450 
enzymes, CYP27A1 and CYP3A4 (1). Interesting, recent 
studies have demonstrated that cholesterol derivatives, 
including 27-hydroxycholesterol, display tumour promoting 
properties (1,3). Mice fed with high cholesterol develop 
nonalcoholic steatohepatitis (NASH) and hepatocellular 
carcinoma (HCC), the primary form of liver cancer (4). 
Like other types of cancer cells, HCC cells proliferate 
at a very high rate thus continuously requiring de novo 
cell membrane lipids and fatty acid synthesis. However, 
the underlying mechanisms by which dietary cholesterol 
contributes to the development of liver cancer is unknown. 
Interestingly, a recent report from Conde de la Rosa et al. (5) 
suggested a key role for steroidogenic acute regulatory 
protein 1 (STARD1) in cholesterol-induced liver cancer 
(Figure 1). STARD1 is one of the 15 distinct mammalian 
proteins (STARD1–STARD15) containing a lipid transfer 
domain spanning ~210 residues that serves as a binding 
interface for lipids (6). STARD1 regulates the rate-
limiting step in steroid hormone production pathway in 
response to hormonal stimuli by transferring cholesterol 
from the outer to the inner mitochondrial membrane, 
allowing the cholesterol side chain to be cleaved by 
the P450 side chain cleavage complex and to generate 
pregnenolone (6). In the liver, mitochondrial cholesterol 
is converted to 27-hydroxycholesterol and ultimately 
into chenodeoxycholic acid (CDCA) through activation 
of the alternative (acidic) mitochondrial pathway of bile 
acids biosynthesis (4,5). How STARD1 contributes to 
HCC pathogenesis is, however, debatable. STARD1 is 
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highly expressed in the livers of patients with NASH-
associated HCC and its expression occurs mainly in 
hepatocytes and—to a lesser extent—in Kupffer cells 
and hepatic stellate cells. Conde de la Rosa et al. (5) 
demonstrated that mice pre-treated with the carcinogen 
diethylnitrosamine (DEN) and then fed with a high fat 
diet (HFD) supplemented with high cholesterol (namely 
HFHC diet) exhibited high levels of STARD1 along 
with enhanced expression of inflammatory signals (i.e., 
TNF-α and CCL2) and HCC markers (i.e., AFP and 
YAP). Importantly, STARD1 gene deletion (STARD1∆Hep) 
in hepatocytes attenuated NASH-driven HCC. This was 
elegantly shown in two distinct animal models fed with 
HFHC diet that most closely resembles human NASH-
driven HCC: (I) the MUP-uPA Tg model where mice 
express transiently high amounts of urokinase plasminogen 
activator (UPA) in hepatocytes resulting in hepatocyte 
ER stress and transient liver damage (events implicated 
in human NASH development); (II) DEN carcinogen 
model where mice develop HCC after DEN injection 
at 15 days post-birth. In addition to using STARD1∆Hep 
mice to test the effect of STARD1 genetic deletion, 
the authors used adenoviral-induced overexpression of 
STARD1 (STARD1OE) in mouse livers to test the effect of 
STARD1 overexpression in response to DEN + HFHC diet 
treatment (5). As anticipated, STARD1 overexpression in 
hepatocytes was associated with an increase in inflammatory 
signals and tumour formation compared to mouse livers 
expressing endogenous STARD1. Strikingly, increased 
HCC formation was evident only in STARD1OE mice fed 
with HFHC but not in STARD1OE mice fed with a regular 
diet, thus supporting the notion that high cholesterol is 
required to prime NASH-driven HCC (5). By comparing 
gene and protein expression in livers of STARD1∆Hep, MUP-
uPA/STARD1∆Hep and STARD1OE mice and respective 
controls, Conde de la Rosa et al. (5) further demonstrated 
that levels of STARD1 in HCC positively correlated with 
an increase in signalling pathways related to bile acid 
synthesis, and in particular, unconjugated bile acids, such as 
cholic acid (CA) and β-muricholic acid (β-MCA), and their 
tauro-conjugated derivatives (Figure 1). The authors also 
found that overexpression of STARD1 was associated with 
elevated levels of genes involved in cell self-renewal and 
pluripotency, suggesting a role for STARD1 in regulating 
stemness in HCC (Figure 1). Interestingly, no correlation 
of expression was found with farnesoid X receptor (FXR), 
a bile acid ligand-activated transcription factor that 
is involved in bile acids synthesis. These data suggest 
Figure 1 Simplified illustration of STARD1 regulation of cholesterol-driven NASH and HCC. Schematic illustration depicting how 
mitochondrial cholesterol contributes to the development of NASH-driven HCC. When the intracellular levels of cholesterol reach 
a certain threshold, it undergoes trafficking to different intracellular organelles, including mitochondria. STARD1 protein mediates 
cholesterol transport to the mitochondrial inner membrane, supplying cholesterol to CYP11A1 to generate pregnenolone in steroidogenic 
tissues, or to CYP27A1 to generate oxysterols (i.e., 27-OH cholesterol) in hepatocytes and other cells expressing this enzyme. Oxysterols are 
then metabolized into bile acids such as CDCA and CA, the two major primary bile acids synthesized in human livers that are conjugated 
with taurine or glycine for secretion into bile. The amount of bile acids accumulated in the liver are, therefore, strictly reliant on STARD1 
expression levels that remain low in a normal functioning liver but increase several folds in response to acute liver injury and chronic liver 
disease, such as NASH—one of most prevalent causes of HCC. CDCA, chenodeoxycholic acid; CA, cholic acid; HCC, hepatocellular 
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that STARD1 regulation of bile acids synthesis during 
development of NASH-driven HCC is independent of 
FXR. In conclusion, Conde de la Rosa et al. (5) unravelled 
a key role for STARD1 in the synthesis of bile acids during 
the development of NASH-HCC (Figure 1). The question 
that remains to be addressed is how levels of STARD1 are 
regulated in human and mouse NASH-HCC. Given that 
the expression of STARD1 in response to acetaminophen 
(APAP)-induced liver injury was found to be dependent 
on c-Jun N-terminal kinase (JNK) (7), a stress activated 
protein kinase implicated in liver homeostasis and cancer 
(8-10), it would be worth to evaluate whether expression of 
STARD1 is regulated by JNK or its downstream effectors (8) 
in NASH and HCC. Further studies are also needed to 
determine whether STARD1 is a potentially targetable 
protein for the treatment of patients with NASH-HCC.
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